Philips M3500B manual Clinical Performance Summary Cardioversion

Clinical Performance Summary - Cardioversion

Clinical Performance Summary - Cardioversion

An international, multicenter, prospective, double-blinded, randomized, clini- cal trial was conducted to assess the effectiveness of the SMART Biphasic waveform in treatment of atrial fibrillation (AF), as compared to monophasic waveforms. The primary objective of the study was to determine the required energy for cardioversion of AF using the SMART Biphasic waveform, as compared with a monophasic damped sine waveform.

This section summarizes the methods and results of this study.

Methods

Patients enrolled for this study were adults scheduled for elective cardiover- sion of AF at one of 11 clinical sites. Clinicians used both a defibrillator deliv- ering the SMART Biphasic waveform, and one delivering a monophasic waveform. A sequence of up to five shocks was administered: four with the initial defibrillator, and a fifth cross-over shock was delivered with the other defibrillator if necessary. The sequence of energy settings was 100J, 150J, 200J through the first three shocks on either type of defibrillator. A fourth shock, if necessary, was delivered at 200J if the initial defibrillator was bipha- sic, and at 360J if the initial defibrillator was monophasic. The cross-over shock was 360J monophasic if the initial defibrillator was biphasic, and 200J biphasic if the initial defibrillator was monophasic. Successful cardioversion was defined as the occurrence of two P waves uninterrupted by atrial fibrilla- tion within 30 seconds of the shock.

Results

Randomization to the use of monophasic or SMART Biphasic defibrillators was done in 212 elective cardioversions involving 210 patients at eleven clin- ical sites in the United States and Europe. Of these, 203 results met the proto- col criteria for inclusion in this analysis. The biphasic and monophasic groups were similar in terms of age, sex, weight, current medical history, cause of heart disease, and estimated ejection fraction.

13-16 Specifications & Safety